Revenue of the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Predicted to Achieve $11.75 Billion by 2030, Driven by 9.4% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the nucleic acid and gene therapies in neuromuscular disorders market from 2026–2035 with trusted insights from The Business Research Company
What are the forecasted starting (2026) and ending (2030) market sizes for the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The nucleic acid and gene therapies in neuromuscular disorders market has experienced robust growth in size over recent years. It is projected to expand from $7.5 billion in 2025 to $8.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. Historically, the market’s growth can be attributed to several factors including limited therapeutic options for nmds, low awareness of gene therapies, the significant cost involved in gene therapy development, a shortage of specialized treatment centers, and slow regulatory approvals.
The market for nucleic acid and gene therapies in neuromuscular disorders is projected to experience substantial growth in the upcoming years, expanding to $11.76 billion by 2030 with a compound annual growth rate (CAGR) of 9.4%. This anticipated expansion during the forecast period is primarily fueled by advancements in adeno-associated virus and postnatal gene therapies, increased research and development investments in NMDs, a rising number of hospitals and specialty clinics providing gene therapies, the growing incidence of neuromuscular disorders, and enhanced patient awareness and advocacy programs. Key trends expected over this period involve the increasing adoption of gene therapy methodologies, intensified development of nucleic acid therapeutics, a sharpened focus on rare neuromuscular disorders, greater investment in personalized medicine strategies, and the broader integration of advanced diagnostic and monitoring instruments.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What Drivers Are Supporting Technological Adoption In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The anticipated expansion of the nucleic acid and gene therapies in neuromuscular disorders market is linked to the rising occurrence of genetic disorders. These disorders are defined as conditions stemming from DNA irregularities within a person, which can be either inherited or triggered by mutations. The surge in genetic disorders can be attributed to several elements, including genetic mutations, environmental factors, shifts in lifestyle, and enhanced diagnostic tools. Nucleic acid and gene therapies address genetic disorders by either rectifying or substituting faulty genes in neuromuscular conditions, thereby aiding in the restoration of typical physiological function. For example, data from May 2024, provided by Cure SMA, a US-based non-profit, indicates that the United States has approximately 9,000 to 9,500 individuals presently affected by Spinal Muscular Atrophy (SMA). Of this total population, 37% are diagnosed with Type 2 SMA. The estimated incidence for this condition stands at 1 in 15,000 births. Consequently, the growing occurrence of genetic disorders is propelling the expansion of the nucleic acid and gene therapies in neuromuscular disorders market.
Which Segments Are Contributing To The Growth Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
What Trends Are Reshaping The Dynamics Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
Leading companies active in the nucleic acid and gene therapies in neuromuscular disorders market are concentrating on developing innovative treatments, such as gene therapy, to tackle the fundamental causes of genetic neuromuscular conditions through targeted gene correction or replacement. Gene therapy involves managing diseases by introducing, modifying, or repairing genetic material within a patient’s cells to correct or substitute defective genes. As an example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, obtained approval from the U.S. Food and Drug Administration for Elevidys, which is the first gene therapy for Duchenne Muscular Dystrophy, specifically for ambulatory pediatric patients aged 4 to 5 years. This therapy is administered as a single intravenous infusion, thereby streamlining the treatment process compared to other therapies that might necessitate ongoing infusions. ELEVIDYS delivers a gene that codes for a shortened form of dystrophin known as micro-dystrophin, a substance vital for muscle function. This pioneering method addresses the underlying genetic flaw by enabling muscle cells to produce a functional version of the dystrophin protein, potentially halting or even reversing disease progression.
Who Are The Core Companies Influencing Trends In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp
Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2026, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Oligonucleotides Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
